JT 002
Alternative Names: JT-002Latest Information Update: 28 Mar 2025
At a glance
- Originator Shanghai JunTop Biosciences
- Class Antiallergics
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Allergic rhinitis
Most Recent Events
- 03 Mar 2025 Phase-II clinical trials in Allergic rhinitis in China (Intranasal) (NCT06861101)